Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients

Journal of Clinical Virology

Volumn 57, Issue 3, 2013, Pages 215-221

  van Velzen, Monique ^a   Missotten, Tom ^b   van Loenen, Freek B ^a,b   Meesters, Roland J W ^a,c   Luider, Theo M ^a   Baarsma, G Seerp ^b   Osterhaus, Albert D M E ^a   Verjans, Georges M G M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ROTTERDAM EYE HOSPITAL   (Netherlands)

^c UNIVERSIDAD DE LOS ANDES   (Colombia)

Author keywords

Acyclovir resistance; Genotyping; Herpes simplex virus type 1; Quasispecies; Thymidine kinase; Uveitis

Indexed keywords

ACICLOVIR; CORTICOSTEROID; GANCICLOVIR; THYMIDINE KINASE; VALACICLOVIR; VIRUS DNA; ANTIVIRUS AGENT;

ADULT; AGED; AMINO ACID SUBSTITUTION; AMPLICON; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; CROSS RESISTANCE; DOSE RESPONSE; FEMALE; FLOW CYTOMETRY; GENE POOL; GENE SEQUENCE; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HERPETIC UVEITIS; HUMAN; IN VITRO STUDY; INTRAOCULAR HYPOTENSION; MALE; MASS SPECTROMETRY; MIDDLE AGED; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PHYLOGENETIC TREE; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TREATMENT DURATION; UVEITIS; VIRAL GENETICS; VIRUS REPLICATION; VISUAL IMPAIRMENT; VITRECTOMY; CHEMISTRY; DNA SEQUENCE; DRUG EFFECT; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MOLECULAR GENETICS; VIROLOGY; DRUG EFFECTS;

ACYCLOVIR; ADULT; AGED; ANTIVIRAL AGENTS; AQUEOUS HUMOR; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; SEQUENCE ANALYSIS, DNA; THYMIDINE KINASE; UVEITIS;

EID: 84891423332     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2013.03.014     Document Type: Article

References (44)

1. Roizman B., Knipe D., Whitley R.J. Herpes simplex viruses. Fields' virology 2007, 2501-2601. Lippincott Williams & Wilkins, Philadelphia. 5th ed. D. Knipe, P. Howley (Eds.).
2. Verjans G., Heiligenhaus A. Herpes simplex virus-induced ocular diseases: detrimental interaction between virus and host. Curr Immunol Rev 2011, 7:310-327.
3. Bacon T.H., Levin M.J., Leary J.J., Sarisky R.T., Sutton D. Herpes simplex virus resistance to acyclovir and penciclovir after two decades of antiviral therapy. Clin Microbiol Rev 2003, 16:114-128.
4. Piret J., Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 2011, 55:459-472.
5. Wilhelmus K.R., Beck R.W., Moke P.S., Dawson C.R., Barron B.A., Jones D.B., et al. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. N Engl J Med 1998, 339:300-306.
6. Danve-Szatanek C., Aymard M., Thouvenot D., Morfin F., Agius G., Bertin I., et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004, 42:242-249.
7. Duan R., de Vries R.D., Osterhaus A.D., Remeijer L., Verjans G.M. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis 2008, 198:659-663.
8. Stranska R., Schuurman R., Nienhuis E., Goedegebuure I.W., Polman M., Weel J.F., et al. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol 2005, 32:7-18.
9. Duan R., de Vries R.D., van Dun J.M., van Loenen F.B., Osterhaus A.D.M.E., Remeijer L., et al. Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis. J Infect Dis 2009, 200:1402-1414.
10. Gaudreau A., Hill E., Balfour H.H., Erice A., Boivin G. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J Infect Dis 1998, 178:297-303.
11. Morfin F., Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003, 26:29-37.
12. Nagamine M., Suzutani T., Saijo M., Hayashi K., Azuma M. Comparison of polymorphism of thymidine kinase gene and restriction fragment length polymorphism of genomic DNA in herpes simplex virus type 1. J Clin Microbiol 2000, 38:2750-2752.
13. van Velzen M., van Loenen F.B., Meesters R.J., de Graaf M., Remeijer L., Luider T., et al. Latent acyclovir-resistant herpes simplex virus type 1 in trigeminal ganglia of immunocompetent individuals. J Infect Dis 2012, 205:1539-1543.
14. van Doornum G.J., Guldemeester J., Osterhaus A.D., Niesters H.G. Diagnosing herpesvirus infections by real-time amplification and rapid culture. J Clin Microbiol 2003, 41:576-580.
15. Meesters R.J., van Kampen J.J., Reedijk M.L., Scheuer R.D., Dekker L.J., Burger D.M., et al. Ultrafast and high-throughput mass spectrometric assay for therapeutic drug monitoring of antiretroviral drugs in pediatric HIV-1 infection applying dried blood spots. Anal Bioanal Chem 2010, 398:319-328.
16. Shiota T., Lixin W., Takayama-Ito M., Iizuka I., Ogata M., Tsuji M., et al. Expression of herpes simplex virus type 1 recombinant thymidine kinase and its application to a rapid antiviral sensitivity assay. Antiviral Res 2011, 91:142-149.
17. Honda M., Okuda T., Hasegawa T., Kurokawa M., Shiraki K., Matsuo K., et al. Effect of long-term, low-dose acyclovir suppressive therapy on susceptibility to acyclovir and frequency of acyclovir resistance of herpes simplex virus type 2. Antiviral Chem Chemother 2001, 12:233-239.
18. Thi T.N., Deback C., Malet I., Bonnafous P., Ait-Arkoub Z., Agut H. Rapid determination of antiviral drug susceptibility of herpes simplex virus types 1 and 2 by real-time PCR. Antiviral Res 2006, 69:152-157.
19. Bohn K., Zell R., Schacke M., Wutzler P., Sauerbrei A. Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus. Antiviral Ther 2011, 16:989-997.
20. Frobert E., Cortay J.C., Ooka T., Najioullah F., Thouvenot D., Lina B., et al. Genotypic detection of acyclovir-resistant HSV-1: characterization of 67 ACV-sensitive and 14 ACV-resistant viruses. Antiviral Res 2008, 79:28-36.
21. Graham D., Larder B.A., Inglis M.M. Evidence that the 'active centre' of the herpes simplex virus thymidine kinase involves an interaction between three distinct regions of the polypeptide. J Gen Virol 1986, 67:753-758.
22. Kudo E., Shiota H., Naito T., Satake K., Itakura M. Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: analysis of clinical isolates from herpetic keratitis patients and laboratory strains. J Med Virol 1998, 56:151-158.
23. Sauerbrei A., Deinhardt S., Zell R., Wutzler P. Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus. Antiviral Res 2010, 86:246-252.
24. Morfin F., Souillet G., Bilger K., Ooka T., Aymard M., Thouvenot D. Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type 1 isolated from bone marrow transplant recipients. J Infect Dis 2000, 182:290-293.
25. Saijo M., Suzutani T., De Clercq E., Niikura M., Maeda A., Morikawa S., et al. Genotypic and phenotypic characterization of the thymidine kinase of ACV-resistant HSV-1 derived from an acyclovir-sensitive herpes simplex virus type 1 strain. Antiviral Res 2002, 56:253-262.
26. Suzutani T., Ishioka K., De Clercq E., Ishibashi K., Kaneko H., Kira T., et al. Differential mutation patterns in thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 clones passaged in the presence of acyclovir or penciclovir. Antimicrob Agents Chemother 2003, 47:1707-1713.
27. Colin J. Ganciclovir ophthalmic gel, 0.15%: a valuable tool for treating ocular herpes. Clin Ophthalmol 2007, 1:441-453.
28. Hoh H.B., Hurley C., Claoue C., Viswalingham M., Easty D.L., Goldschmidt P., et al. Randomised trial of ganciclovir and acyclovir in the treatment of herpes simplex dendritic keratitis: a multicentre study. Br J Ophthalmol 1996, 80:140-143.
29. Kaufman H.E., Haw W.H. Ganciclovir ophthalmic gel 0.15%: safety and efficacy of a new treatment for herpes simplex keratitis. Curr Eye Res 2012, 37:654-660.
30. Tabbara K.F., Al Balushi N. Topical ganciclovir in the treatment of acute herpetic keratitis. Clin Ophthalmol 2010, 4:905-912.
31. Safrin S., Elbeik T., Phan L., Robinson D., Rush J., Elbaggari A., et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1994, 38:1246-1250.
32. Kimura S.J. Herpes simplex uveitis: a clinical and experimental study. Trans Am Ophthalmol Soc 1962, 60:440-470.
33. Sauerbrei A., Eichhorn U., Hottenrott G., Wutzler P. Virological diagnosis of herpes simplex encephalitis. J Clin Virol 2000, 17:31-36.
34. Verjans G.M., Hintzen R.Q., van Dun J.M., Poot A., Milikan J.C., Laman J.D., et al. Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A 2007, 104:3496-3501.
35. Frobert E., Ooka T., Cortay J.C., Lina B., Thouvenot D., Morfin F. Resistance of herpes simplex virus type 1 to acyclovir: thymidine kinase gene mutagenesis study. Antiviral Res 2007, 73:147-150.
36. Sauerbrei A., Bohn K., Heim A., Hofmann J., Weissbrich B., Schnitzler P., et al. Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2. Antiviral Ther 2011, 16:1297-1308.
37. Stranska R., van Loon A.M., Polman M., Beersma M.F., Bredius R.G., Lankester A.C., et al. Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients. Antiviral Ther 2004, 9:565-575.
38. Kussmann-Gerber S., Kuonen O., Folkers G., Pilger B.D., Scapozza L. Drug resistance of herpes simplex virus type 1 - structural considerations at the molecular level of the thymidine kinase. Eur J Biochem 1998, 255:472-481.
39. Burrel S., Deback C., Agut H., Boutolleau D. Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. Antimicrob Agents Chemother 2010, 54:4833-4842.
40. Sauerbrei A., Liermann K., Bohn K., Henke A., Zell R., Gronowitz S., et al. Significance of amino acid substitutions in the thymidine kinase gene of herpes simplex virus type 1 for resistance. Antiviral Res 2012, 96:105-107.
41. Nugier F., Colin J.N., Aymard M., Langlois M. Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey. J Med Virol 1992, 36:1-12.
42. Shin Y.K., Cai G.Y., Weinberg A., Leary J.J., Levin M.J. Frequency of acyclovir-resistant herpes simplex virus in clinical specimens and laboratory isolates. J Clin Microbiol 2001, 39:913-917.
43. Sarisky R.T., Nguyen T.T., Duffy K.E., Wittrock R.J., Leary J.J. Difference in incidence of spontaneous mutations between Herpes simplex virus types 1 and 2. Antimicrob Agents Chemother 2000, 44:1524-1529.
44. Erlich K.S., Mills J., Chatis P., Mertz G.J., Busch D.F., Follansbee S.E., et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989, 320:293-296.